Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | HTT | P42858 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | MMP14 | P50281 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | ALOX15B | O15296 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroxine SCHEMBL29389908 | 1.00 | KDM4E (1.00) | KDM4EHSP90AA1MEN1HTTKMT2A | |
| Chloroxine SCHEMBL3350 | 1.00 | KDM4E (1.00) | KDM4EHSP90AA1MEN1HTTKMT2A | |
| Chloroxine SCHEMBL6677225 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1HTTKMT2A | |
| Chloroxine SCHEMBL9135479 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1HTTKMT2A | |
| Chloroxine SCHEMBL22734873 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1HTTKMT2A | |
| Chloroxine SCHEMBL4293183 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1HTTKMT2A | |
| Chloroxine SCHEMBL231205 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1HTTKMT2A | |
| Chloroxine SCHEMBL4297732 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1HTTKMT2A | |
| Chloroxine SCHEMBL31016232 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1HTTKMT2A | |
| Chloroxine SCHEMBL28905314 | 0.98 | KDM4E (0.96) | KDM4EHSP90AA1MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180881-A1 | METHODS FOR DECREASING RESISTANCE TO CHEMOTHERAPY | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2024-06-06 | — | — | US | claimed |
| WO-2023091964-A2 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF TUMOR METASTASIS AND HORIZONTAL GENE TRANSFER | THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) | 2023-05-25 | — | — | WO | claimed |
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2026090318-A2 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | DEFY-Tech Labs, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108446-A1 | HYDROXYQUINOLINE COMPOUNDS AND METHODS OF USE AS PIGMENT MODIFYING AGENTS | GERMANAS JURIS (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108444-A1 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | DEFY TECH LABS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| US-20260085341-A1 | Using Multiple Heteroresistance to Guide Combination Antimicrobial Regimens | UNIV EMORY (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-11400106-B2 | Methods for inhibiting microbe growth | MCMASTER UNIVERSITY (CA) | 2022-08-02 | — | — | US | disclosed |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022155544-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | Zander Biologics, Inc (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220168384-A1 | Anti-Bacterial Combination Therapy | MCMASTER UNIVERSITY (CA) | 2022-06-02 | — | — | US | disclosed |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | KCL THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| EP-3960729-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | Neoculi Pty Ltd (AU) | 2022-03-02 | — | — | EP | disclosed |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | KCL THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108444-A1 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | LIPA, LIPC, ACACA | KDM4E 2194/4885HSP90AA1 1683/4885MEN1 3824/4885 |
| US-20260085341-A1 | Using Multiple Heteroresistance to Guide Combination Antimicrobial Regimens | Q6ZSR9, AMPD2, AMPD1 | KDM4E 1937/4885HSP90AA1 1124/4885MEN1 3172/4885 |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | CYP2C19, PAICS, CYP2B6 | KDM4E 3899/4885HSP90AA1 2775/4885MEN1 2692/4885 |
| US-20260108446-A1 | HYDROXYQUINOLINE COMPOUNDS AND METHODS OF USE AS PIGMENT MODIFYING AGENTS | TYR, TFEB, MC1R | KDM4E 1218/4885HSP90AA1 2473/4885MEN1 3765/4885 |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | NR2F2, NR2E3, NR2C2 | KDM4E 1747/4885HSP90AA1 3378/4885MEN1 4656/4885 |
| US-11400106-B2 | Methods for inhibiting microbe growth | MMP8, BPGM, CAPG | KDM4E 3158/4885HSP90AA1 962/4885MEN1 2205/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | KDM4E 1515/4885HSP90AA1 2910/4885MEN1 2827/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | KDM4E 2468/4885HSP90AA1 1524/4885MEN1 4053/4885 |
| US-20240180881-A1 | METHODS FOR DECREASING RESISTANCE TO CHEMOTHERAPY | BLM, RAD54L, XRCC5 | KDM4E 1367/4885HSP90AA1 2960/4885MEN1 1182/4885 |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | NR4A2, NR2C2, NR0B2 | KDM4E 3440/4885HSP90AA1 2110/4885MEN1 3917/4885 |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | NR4A2, NR2C2, NR2F2 | KDM4E 3502/4885HSP90AA1 2026/4885MEN1 4260/4885 |
| US-20220168384-A1 | Anti-Bacterial Combination Therapy | TST, SLC11A2, HAMP | KDM4E 4127/4885HSP90AA1 173/4885MEN1 4295/4885 |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | KDM4E 2931/4885HSP90AA1 931/4885MEN1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.